Search
Research
In vitro antibacterial activity of Western Australian honeys, and manuka honey, against bacteria implicated in impetigoImpetigo is a contagious skin disease caused by Staphylococcus aureus and Streptococcus pyogenes. Without treatment, impetigo may be recurrent, develop into severe disease, or have serious, life-threatening sequelae. Standard treatment consists of topical or systemic antibiotic therapy (depending on severity), however, due to antibiotic resistance some therapies are increasingly ineffective.
Research
Are scabies and impetigo “normalised”? A cross-sectional comparative study of hospitalised children in northern Australia assessing clinical recognitionScabies and impetigo infections are under-recognised and hence under-treated by clinicians
Research
Scabies and risk of skin sores in remote Australian Aboriginal communities: A self-controlled case series studyThe association between scabies and skin sores is highly significant and indicates a causal relationship
Research
Burden of skin disease in two remote primary healthcare centres in northern and central AustraliaSkin infections are an under-appreciated and dominant reason for presentation to primary healthcare centres in these indigenous communities
Research
Ascertaining infectious disease burden through primary care clinic attendance among young Aboriginal children living in four remote communities in Western AustraliaImproved public health measures targeting bacterial skin infections are needed to reduce this high burden of skin infections in Western Australia
Research
Comparison of group A streptococcal titres in healthy children and those with pharyngitis and skin infectionsRates of acute rheumatic fever, a sequelae of group A Streptococcal (GAS) infection, remain unacceptably high in Indigenous Māori and Pacific children in New Zealand. This prospective study aimed to describe GAS antibody titres in healthy children (5–14 years) by ethnicity, and to determine how paired titres vary with GAS culture positive and negative pharyngitis, and GAS skin infections.
Research
Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)-an open-labelled pilot randomized controlled trialCombination antibiotic therapy with an antitoxin agent, such as clindamycin, is included in some guidelines for severe, toxin-mediated Staphylococcus aureus infections. The evidence to support this practice is currently limited to in vitro, animal and observational human case-series data, with no previous randomized controlled trials (RCTs).
News & Events
$1 million funding boost to help Aboriginal kids with skin infectionsThanks to a $1 million funding grant, Dr Asha Bowen from The Kids Research Institute Australia is on track to change Aboriginal children's skin infection statistics.
News & Events
Prestigious invite for WA infectious disease expertsTwo Perth clinician-scientists have been recognised as national leaders in infectious disease research after being elected as Fellows of the esteemed Australian Academy of Health and Medical Sciences.
Research
Does adjunctive clindamycin have a role in Staphylococcus aureus bacteremia? A protocol for the adjunctive treatment domain of the S. aureus Network Adaptive Platform (SNAP) randomized controlled trialThe use of adjunctive antibiotics directed against exotoxin production in Staphylococcus aureus bacteremia (SAB) is widespread, and is recommended in many guidelines, but there is limited evidence underpinning this.